Publication
Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
| dc.contributor.author | Valentim Gonçalves, A | |
| dc.contributor.author | Pereira-da-Silva, T | |
| dc.contributor.author | Galrinho, A | |
| dc.contributor.author | Rio, P | |
| dc.contributor.author | Branco, LM | |
| dc.contributor.author | Soares, R | |
| dc.contributor.author | Feliciano, J | |
| dc.contributor.author | Ilhão Moreira, R | |
| dc.contributor.author | Cruz Ferreira, R | |
| dc.date.accessioned | 2020-02-05T16:13:23Z | |
| dc.date.available | 2020-02-05T16:13:23Z | |
| dc.date.issued | 2019-06-18 | |
| dc.description.abstract | Sacubitril/Valsartan (LCZ696) reduced sudden cardiac death in the PARADIGM-HF trial. However, the mechanism by which LCZ696 reduces ventricular arrhythmias remains unclear. The aim of this study was to compare electrocardiographic (ECG) parameters and mechanical dispersion index, assessed by left ventricular (LV) global longitudinal strain (GLS), before and after LCZ696 therapy. We prospectively evaluated chronic Heart Failure (HF) patients with LV ejection fraction ≤40%, despite optimal medical and device therapy, in which LCZ696 therapy was started, while no additional HF treatment was expected to change. ECG and transthoracic echocardiographic data were gathered in the week before starting LCZ696 and at six months of therapy. A semiautomated analysis of LV GLS was performed and mechanical dispersion index was defined as the standard deviation from 16 time intervals corresponding to each LV segment. Of the 42 patients, 35 completed the six month follow-up, since two patients died and five discontinued treatment for adverse events. QTc interval (451.9 vs. 426.0 ms, p < 0.001), QRS duration (125.1 vs. 120.8 ms, p = 0.033) and mechanical dispersion index (88.4 vs. 78.1 ms, p = 0.036) were significantly reduced at six months. LCZ696 therapy is associated with a reduction in QTc interval, QRS duration and mechanical dispersion index as assessed by LV GLS. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | J Clin Med. 2019 Jun 18;8(6). pii: E869. | pt_PT |
| dc.identifier.doi | 10.3390/jcm8060869 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/3409 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Multidisciplinary Digital Publishing Institute | pt_PT |
| dc.subject | HSM CAR | pt_PT |
| dc.subject | QRS Interval | pt_PT |
| dc.subject | QTc Interval | pt_PT |
| dc.subject | Sacubitril-Valsartan | pt_PT |
| dc.subject | Antiarrhythmic Effect | pt_PT |
| dc.subject | Mechanical Dispersion Index | pt_PT |
| dc.title | Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement? | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 6 | pt_PT |
| oaire.citation.startPage | 869 | pt_PT |
| oaire.citation.title | Journal of Clinical Medicine | pt_PT |
| oaire.citation.volume | 8 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |